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INTRODUCTION
Clozapine is an effective drug for the treatment of refrac-
tory schizophrenia. It has a few extrapyramidal side effects
and rarely leads to tardive dyskinesia, but it can induce agran-
ulocytosis, seizures, sedation, obsessive-compulsive symp-
toms, weight gain, and sialorrhea. In addition, urinary sys-
tem side effects, especially enuresis, occur in 6% to 44.3%
of patients (1, 2). These side effects can cause medical com-
plications, contribute to noncompliance, and consequently
decrease the quality of life of patients.
The mechanisms of enuresis caused by clozapine include
overflow incontinence after urinary retention due to the anti-
muscarinic action of clozapine (3), the cholinomimetic activi-
ty of clozapine (4), and decreased internal urethral sphincter
tone caused by an a-1 adrenergic blockade effect (5). In addi-
tion, enuresis has been attributed to non-specific clozapine
action such as its excessive sedative action, the lowering of
the seizure threshold, and constipation exacerbating urinary
retention and overflow (6). Based on these mechanisms, treat-
ments such as decreasing the dose of clozapine, replacing it
with other antipsychotic drugs with low anticholinergic effects,
and using tricyclic antidepressants, trihexyphenidyl, oxybu-
tynin, and ephedrine have been used, but contrary results have
been reported (4, 5, 7-9). The specific mechanisms of cloza-
pine-induced enuresis have not been determined. Kantrowitz
has reported that risperidone-induced enuresis improved after
changing from risperidone to aripiprazole or olanzapine, and
after stopping the nighttime dosage. He explained that mech-
anisms for enuresis included andrenergic blockade via a-1
and blockade of pudendal reflexes via antagonism of 5-HT2
or 3 (10).
In addition, antipsychotic-induced enuresis can be explain-
ed by decreased dopamine transmission in the basal ganglia
or an imbalance between dopamine and norepinephrine with-
in the basal ganglia (11). Here, we report two cases in which
combination treatment with clozapine and aripiprazole, a
dopamine partial agonist that works as a D2 antagonist in a
hyperdopaminergic state and as a D2 agonist in a hypodo-
paminergic state (12), was used effectively for patients with
clozapine-induced enuresis.
CASE REPORTS
Case 1
A 52-yr-old man was diagnosed with paranoid type schizo-
phrenia at age 18. Although he had been hospitalized for
treatment several times, auditory hallucinations, persecuto-
ry delusions, and delusions of reference persisted, and he was
treated with clozapine 350 mg/day after being hospitalized
in the Psychiatry Department of Inha University Hospital in
December 1997. Because his psychotic symptoms improved
with no side effects except sialorrhea, he was discharged from
the hospital on the 26th day of hospitalization and treated
as an outpatient. During outpatient treatment, he respond-
ed to his drugs well and his symptoms were stable. While
receiving clozapine 200 mg/day and amitriptyline 25 mg/
day for sialorrhea in June 1998, he experienced enuresis two
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Use of Aripiprazole in Clozapine Induced Enuresis: Report of Two Cases
This report describes the efficacy of combined use of aripiprazole in the treatment of
a patient with clozapine induced enuresis. Aripiprazole acts as a potential dopamine
partial agonist and the dopamine blockade in the basal ganglia might be one of the
causes of urinary incontinence and enuresis. We speculate that aripiprazole func-
tioned as a D2 agonist in hypodopaminergic state of basal ganglia caused by cloza-
pine and maintained dopamine level that would improve enuresis ultimately.
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as limiting water intake after 20:00 and urinating before going
to bed, and treatment with bethanechol 5 mg/day were some-
what effective, enuresis one to three times per week persist-
ed. After starting combination treatment with clozapine 200
mg/day and aripiprazole 10 mg/day from 5 mg/day initially
in May 2005, he had no enuresis from August 2005, and the
aripiprazole was stopped in September. Subsequently, enure-
sis two to three times per month was observed in November
2005, and clozapine 200 mg/day and aripiprazole 10 mg/day
orally recommenced in January 2006; subsequently, enure-
sis ceased. After discontinuing the aripiprazole in May 2006,
at the patient’s request, enuresis started again (approximate-
ly two times per week), but no enuresis occurred in Decem-
ber 2006.
Case 2
A 27-yr-old man diagnosed with paranoid type schizophre-
nia at age 14 had been hospitalized for treatment several times,
but his persecutory delusions and violent behavior persisted.
Treatment using clozapine was started in September 1997
when he was hospitalized at Seoul National University Hos-
pital. Considering the distance to the hospital, he was trans-
ferred to the Psychiatry Department of Inha University Hos-
pital for treatment in September 1997. Because the admin-
istration of clozapine 250 mg/day led to some improvement
in his symptoms, and no side effects except sialorrhea were
observed, he left the hospital on the 42nd day of hospitaliza-
tion. During outpatient treatment, persecutory ideation and
sialorrhea continued. In August 1999, he experienced a con-
vulsion while taking clozapine 425 mg/day and benztropine
3 mg/day. In August 2000, he had a second convulsion while
being treated with clozapine 400 mg/day and benztropine 3
mg/day. Obsessive-compulsive symptoms began in August
2001 and persisted; the patient took fluvoxamine 100 mg/
day in August 2002 and discontinued benztropine in Novem-
ber 2002. In August 2003, while taking clozapine 450 mg/
day and fluvoxamine 100 mg/day, enuresis occurred two to
three times per week. Despite treatment with clozapine 400
mg/day, benztropine 2 mg/day, and fluvoxamine 100 mg/day,
along with behavior education, he experienced enuresis nearly
every day. The enuresis improved in April 2005, after he was
treated with clozapine 300 mg/day, benztropine 2 mg/day,
fluvoxamine 50 mg/day, and aripiprazole 10 mg/day. Since
May 2005, he had been taking clozapine 350 mg/day, ben-
ztropine 2 mg/day, fluvoxamine 50 mg/day, and aripiprazole
15 mg/day, and no enuresis occurred. In August 2005, the
aripiprazole was discontinued because the patient said that
he became sick and nervous after taking it; subsequently, he
had no enuresis. In March 2006, enuresis was observed once
to twice per month; subsequently, he took additional arip-
iprazole 10 mg/day and had no enuresis with no change in
previous medications.
DISCUSSION
In the first case, enuresis began six months after adminis-
tering clozapine and persisted for seven years. Combination
treatment with aripiprazole without reducing the clozapine
dose had a rapid effect, and the enuresis disappeared in three
months. Subsequently, the enuresis improved or worsened
repeatedly according to whether the patient was taking or
not taking aripiprazole, respectively. Although the occurrence
of enuresis could reflect transient episodes (6), it was thought
to be related to the treatment effect of aripiprazole, based on
the temporal relationship between the administration of arip-
iprazole and the occurrence of enuresis. In addition, even with
combination treatment with amitriptyline, which has been
used to treat enuresis (8), the enuresis began somewhat later
contrary to the results of previous studies, that reported that
it began within several hours to two to four weeks after using
clozapine (13). Therefore, the occurrence of enuresis should
be monitored, even when the patient is on a stable dose of
clozapine.
In the second case, the patient experienced enuresis after
taking clozapine for six years, and it continued for approxi-
mately 20 months. Subsequently, it improved in one month
following combination treatment with aripiprazole. Subse-
quently, the enuresis improved or worsened repeatedly, accord-
ing to whether the patient was taking or not taking aripipra-
zole, respectively.
Although combination treatment with benztropine and a
selective serotonin reuptake inhibitor can increase urinary
incontinence and the risk of enuresis (14), there is little rela-
tionship between enuresis and benztropine and fluvoxamine,
considering the timing of benztropine and fluvoxamine intake
and the timing of enuresis. The improvement of enuresis in
this case cannot be explained by aripiprazole alone because
the dose of clozapine was also decreased in the combination
treatment. However, the enuresis improved soon after admin-
istering aripiprazole, and it did not recur after increasing the
dose of clozapine to the previous level. Moreover, when enuresis
recurred, without changing previous medications but after
adding aripiprazole, enuresis improved in one month. There-
fore, the aripiprazole was thought to be related to the improve-
ment in the clozapine-induced enuresis. The patient also expe-
rienced enuresis relatively late in his treatment, which indi-
cated the need for continuous monitoring of the occurrence
of enuresis.
The treatment effects of aripiprazole on clozapine-induced
enuresis could be attributed to the specific pharmacological
action of dopamine partial agonists. Ambrosini suggested
that urinary continence is correlated with the catecholamine
system within the basal ganglia and reported that drugs that
increase noradrenergic activity and dopamine agonists improve
enuresis because it occurs in a hypodopaminergic and nora-
drenergic-deficit state (11). In addition, diseases that decrease
dopamine within the basal ganglia, e.g., Parkinson’s disease
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and enuresis, and the administration of amantadine, a dopa-
mine agonist, improves enuresis (15, 16). In our patients, we
speculate that aripiprazole functioned as a D2 agonist in the
hypodopaminergic basal ganglia caused by clozapine and
maintained a dopamine level that ultimately improved the
enuresis.
Moreover, considering that selective 5-HT1A antagonists
inhibit bladder contraction (17), aripiprazole, which is a 5-
HT1A partial agonist, could reduce bladder dysfunction com-
pared to clozapine. In addition, because aripiprazole has a
small a-1 adrenergic blockade effect and little antimuscarinic
effect or sedative action, even combination treatment with
two neuroleptics would not worsen the enuresis.
This case study is meaningful because it presents cases in
which clozapine-induced enuresis was improved using com-
bination treatment with aripiprazole. More systemic studies
are needed to determine the specific effects of aripiprazole on
clozapine-induced enuresis.
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